Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanotropil Novo
- Development stage
- Phase 1
- Lead developer
- Valenta Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nanotropil Novo is a nootropic small molecule drug containing fonturacetam (also known as phenylpiracetam), developed and marketed by Valenta Pharmaceuticals. It is indicated for the treatment of various central nervous system (CNS) disorders, including cognitive impairment, memory loss, attention deficits, and metabolic or vascular cerebral disorders. The drug acts as a neuromodulator, stimulating cholinergic and glutamatergic neurotransmitter systems, which leads to increased levels of acetylcholine, glutamate, dopamine, and norepinephrine in the brain. It exhibits antiamnestic, anticonvulsant, anxiolytic, and psychostimulating properties. Nanotropil Novo was launched in Russia in May 2020 as a successor to the brand Phenotropil and is included in the Russian list of Vital and Essential Medicines.
- Brand names
- Nanotropil Novo
- Other names
- fonturacetamphenylpiracetamPhenotropil
02
Targets
AMPAR (AMPA receptor)NMDAR (Glutamate receptor ionotropic, NMDA)DAT (Dopamine plasma membrane transport protein)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)
Beyond the preview
Go deeper on Nanotropil Novo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanotropil Novo.